Department of Critical Care Medicine, ASO Iizuka Hospital, Iizuka city, Fukuoka, Japan.
Department of Clinical Engineering, ASO Iizuka Hospital, Iizuka city, Fukuoka, Japan.
Perfusion. 2022 Sep;37(6):570-574. doi: 10.1177/02676591211011039. Epub 2021 Apr 19.
Extracorporeal membrane oxygenation (ECMO) and Continuous renal replacement therapy (CRRT) are treatments for critically ill patients with respiratory failure and acute kidney injury. However, no reliable factors have been identified to predict survival in patients treated with both ECMO and CRRT. The aim of this study was to identify prognostic factors for discharging intensive care unit (ICU) patients who required CRRT during ECMO.
We retrospectively analyzed data from patients who required CRRT in addition to the ECMO, between April 2015 and March 2018. The patients were divided into two groups: patients who survived and patients who died during ICU hospitalization. We determined their demographic and clinical characteristics, Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, Simplified Acute Physiology Score II (SAPS II) scores, and sequential organ failure assessment (SOFA) scores. Further, we assessed whether these characteristics differed between individuals who did or did not survive the ICU hospitalization.
We found that the APACHE II and SAPS II scores differed significantly between both ECMO and CRRT treated patients who did or did not survive hospitalization. Further, intracranial hemorrhage during ECMO and CRRT therapy was associated with lower survival rate.
Using APACHE II and SAPS II scores might be helpful in making treatment decisions for patients treated with ECMO and CRRT. Intracranial hemorrhage could be a poor prognostic factor. Our findings indicate the potential utility of APACHE II and SAPS II scores to predict mortality in patients treated with both ECMO and CRRT.
体外膜肺氧合(ECMO)和持续肾脏替代治疗(CRRT)是治疗呼吸衰竭和急性肾损伤的危重症患者的方法。然而,尚未确定可靠的因素来预测同时接受 ECMO 和 CRRT 治疗的患者的生存情况。本研究旨在确定需要在 ECMO 期间进行 CRRT 的 ICU 患者出院的预后因素。
我们回顾性分析了 2015 年 4 月至 2018 年 3 月期间需要除 ECMO 以外的 CRRT 的患者的数据。患者分为两组:在 ICU 住院期间存活的患者和死亡的患者。我们确定了他们的人口统计学和临床特征、急性生理学和慢性健康评估 II 评分(APACHE II)、简化急性生理学评分 II(SAPS II)和序贯器官衰竭评估(SOFA)评分。此外,我们评估了这些特征在 ICU 住院期间存活和未存活的患者之间是否存在差异。
我们发现,在接受 ECMO 和 CRRT 治疗的患者中,存活和未存活的患者的 APACHE II 和 SAPS II 评分差异显著。此外,ECMO 和 CRRT 治疗期间的颅内出血与较低的生存率相关。
使用 APACHE II 和 SAPS II 评分可能有助于为接受 ECMO 和 CRRT 治疗的患者做出治疗决策。颅内出血可能是预后不良的因素。我们的研究结果表明,APACHE II 和 SAPS II 评分可能有助于预测同时接受 ECMO 和 CRRT 治疗的患者的死亡率。